Valence 로고
인기
로그인
Loading data for BMRN — first visit, this takes a few seconds.

관심목록에 추가

BioMarin Pharmaceutical I...

NasdaqGS: BMRN · 실시간 가격 · USD
66.70
-0.98 (-1.45%)
종가 기준: Aug 27, 2026, 3:59 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

BioMarin Pharmaceutical Inc.(BMRN) 주가, 분석 및 데이터

-1.45%
매수호가63.89
시가총액12.64B
매출 (ttm)3.41B
순이익 (ttm)72.97M
0.23
0.37
176.46
10.09
P/B (ttm)2.00
P/S (ttm)3.71
실적 발표일Oct 26, 2026
매도호가66.73
거래량1,440,947
평균 거래량 (20일)2,108,156
시가67.55
전일 종가67.68
일중 범위66.52 - 68.34
52주 범위49.26 - 70.98
애널리스트n/a
목표주가n/a
배당n/a
배당락일n/a

BMRN 소개

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a onc...

[더 보기]
산업 Biotechnology
섹터 Healthcare
IPO 일자 Jul 26, 1999
직원 수 3,221
상장 거래소 NasdaqGS
티커 BMRN
웹사이트 https://www.biomarin.com
전체 기업 정보

재무 실적

2025년 BioMarin Pharmaceutical의 매출은 3.22B로, 전년 2.85B 대비 12.87% 증가했습니다. 순이익은 348.9M로, -18.26% 감소했습니다.

재무제표

어닝 서프라이즈

BioMarin Pharmaceutical가 Aug 6, 2026에 분기 실적을 발표했습니다:
  • 매출 $989.71M 예상치 하회 $0, 및 19.91% 전년 대비 성장.
  • EPS 1.2 예상치 상회 0.25, 및 -16.67% 전년 대비 감소.

다음 실적 발표

BioMarin Pharmaceutical Inc.의 실적 발표 예정일은 Oct 26, 2026, 장 마감 후입니다.
애널리스트 예상 매출은 ... 업그레이드
news image

6일 전 · Simply Wall St.

BioMarin Pharmaceutical (BMRN) Agrees $490 Million Deal For Oral Rare Bone Disease Program

BioMarin Pharmaceutical (NasdaqGS:BMRN) agreed to acquire Alesta Therapeutics for up to US$490 million to expand its rare disease portfolio. The deal centers on ALE1, an oral small molecule candidate ...

news image

1주 전 · StockStory

Therapeutics Stocks Q2 Results: Benchmarking BioMarin Pharmaceutical (NASDAQ:BMRN)

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at therapeutics stocks, starting with BioMar...

news image

1주 전 · StockStory

Why BioMarin Pharmaceutical (BMRN) Stock Is Up Today

Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 3.3% in the afternoon session after the company agreed to acquire Alesta Therapeutics, a clinical-stage biotech company.

news image

1주 전 · Insider Monkey

BioMarin Pharmaceutical (BMRN)’s Alesta Deal Adds New Growth Potential in Rare Diseases

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is expanding its rare-disease business with the acquisition of Alesta Therapeutics for $275 million upfront. The deal gives BioMarin access to ALE1, an oral ...

news image

1주 전 · Quartz

BioMarin acquiring Alesta Therapeutics for $275 million

The deal gives BioMarin access to ALE1, a small-molecule drug in early-stage trials that could become the first oral therapy for hypophosphatasia

2 페이지 중 1